00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
04:17 , Dec 8, 2017 |  BC Week In Review  |  Financial News

Atox Bio raises $30M series F

On Dec. 4, Atox Bio Ltd. (Ness Ziona, Israel) raised $30 million in a series F round led by new investor Arix Bioscience plc (LSE:ARIX), which contributed $8 million. Fellow new investors Adams Street Partners...
19:35 , Dec 4, 2017 |  BC Extra  |  Financial News

Atox Bio raises $30M series F

Atox Bio Ltd. (Ness Ziona, Israel) raised $30 million in a series F round led by new investor Arix Bioscience plc (LSE:ARIX), which contributed $8 million. Fellow new investors Adams Street Partners and Asahi Kasei...
07:00 , May 11, 2015 |  BC Week In Review  |  Company News

Evotec, Asahi Kasei deal

Evotec will use its ion channel platform to identify inhibitors of multiple ion channel targets provided by Asahi’s Asahi Kasei Pharma Corp. subsidiary. Evotec declined to financial details, and Asahi could not be reached. Evotec...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Company News

Asahi Kasei Corp., Zoll Medical Corp. deal

Asahi completed its subsequent tender offer for Zoll, acquiring 20.7 million shares (93.05%) at $93 per share, or about $1.9 billion in cash. Asahi plans to acquire the remaining shares at the same price through...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Company News

Asahi Kasei Corp., Zoll Medical Corp. deal

Asahi began its tender offer to acquire Zoll for $93 per share in cash, or about $2.2 billion. The offer will expire at midnight EDT on April 20 (see BioCentury, March 19). Asahi Kasei Corp....
07:00 , Mar 19, 2012 |  BC Week In Review  |  Company News

Asahi Kasei, Zoll Medical deal

Asahi will acquire Zoll for $93 per share in cash, or about $2.2 billion. The price is a 24% premium to Zoll's close of $75.10 on March 9, before the deal was announced. Any shares...
00:18 , Mar 13, 2012 |  BC Extra  |  Company News

Asahi Kasei to acquire Zoll Medical for $2.2 billion

Asahi Kasei Corp. (Tokyo:3407) will acquire Zoll Medical Corp. (NASDAQ:ZOLL) for $93 per share in cash, or about $2.2 billion. The price is a 24% premium to Zoll's close of $75.10 on Friday, before the...
07:00 , Apr 23, 2007 |  BC Week In Review  |  Company News

Actelion, Asahi Kasei Corp. deal

ATLN ended a deal with Asahi to develop fasudil for pulmonary arterial hypertension (PAH) and angina for undisclosed reasons. ATLN gained rights to develop the Rho kinase inhibitor in North America and Europe through its...